Oculis Holding AG (OCS)
$7.62-3.30%Close
SELLCRISIS · day 25
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $436M
- Beta
- 0.23
- P/E (TTM)
- -4.53
- Short % float
- 4.78%
- Days to cover
- 6.5
- SI change
- +14.1%
- 1W
- -12.61%
- 1M
- -28.11%
- vs SPY 1W
- -12.48%
- vs SPY 1M
- -30.62%
Industry peers
FMP comparable companies · ranked by market cap
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 0
- VALUE
- 2
- GROWTH
- 4
- GARP
- 3
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-25.8%
REV YoY-
ROE-42.9%
EPS YoY-
ROA-31.8%
GROSS35
OP-35874
NET-32780
[VALUATION]
P/E TTM-4.53
P/E FWD-
SECTOR PE14.82
INDUSTRY PE13.84
P/B1.77
P/FCF-
EV/EBITDA-4.66
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E1.16
ALTMAN Z-
CURR RATIO8.35
ND/EBITDA-
BETA0.23
Company news
FAQ
- What is LOPJLB’s current signal on OCS?
- LOPJLB’s latest quantitative signal on Oculis Holding AG (OCS) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is OCS in?
- Oculis Holding AG (OCS) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Oculis Holding AG (OCS) do?
- Oculis Holding AG is a biopharmaceutical company in the clinical development stage, specializing in the creation of innovative eye drop medications for various ocular conditions, addressing both the anterior and posterior segments of the eye. A key asset in its therapeutic portfolio is OCS-01, a topical formulation of dexamethasone, currently progressing through Phase 3 clinical trials for the …